Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
19.3M
-
Number of holders
-
261
-
Total 13F shares, excl. options
-
23.2M
-
Shares change
-
-1.51M
-
Total reported value, excl. options
-
$2.31B
-
Value change
-
-$159M
-
Put/Call ratio
-
6.4
-
Number of buys
-
88
-
Number of sells
-
-172
-
Price
-
$99.54
Significant Holders of LIGAND PHARMACEUTICALS INC - Common Stock (LGND) as of Q3 2019
337 filings reported holding LGND - LIGAND PHARMACEUTICALS INC - Common Stock as of Q3 2019.
LIGAND PHARMACEUTICALS INC - Common Stock (LGND) has 261 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 23.2M shares
.
Largest 10 shareholders include BlackRock Inc. (2.46M shares), VANGUARD GROUP INC (1.64M shares), JANUS HENDERSON GROUP PLC (1.57M shares), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (1.34M shares), STATE STREET CORP (1.27M shares), RENAISSANCE TECHNOLOGIES LLC (1.22M shares), CARDINAL CAPITAL MANAGEMENT LLC /CT (893K shares), Conestoga Capital Advisors, LLC (633K shares), MACQUARIE GROUP LTD (560K shares), and Stephens Investment Management Group LLC (511K shares).
This table shows the top 261 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.